- Home
- NBXG vs COLL Comparison
NBXG vs COLL Comparison
Compare NBXG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- COLL
- Stock Information
- Founded
- NBXG 2021
- COLL 2002
- Country
- NBXG United States
- COLL United States
- Employees
- NBXG N/A
- COLL N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- NBXG Finance
- COLL Health Care
- Exchange
- NBXG Nasdaq
- COLL Nasdaq
- Market Cap
- NBXG 989.2M
- COLL 910.2M
- IPO Year
- NBXG N/A
- COLL 2015
- Fundamental
- Price
- NBXG $12.30
- COLL $29.85
- Analyst Decision
- NBXG
- COLL Strong Buy
- Analyst Count
- NBXG 0
- COLL 5
- Target Price
- NBXG N/A
- COLL $43.60
- AVG Volume (30 Days)
- NBXG 243.7K
- COLL 456.4K
- Earning Date
- NBXG 01-01-0001
- COLL 05-08-2025
- Dividend Yield
- NBXG 10.25%
- COLL N/A
- EPS Growth
- NBXG N/A
- COLL 43.56
- EPS
- NBXG N/A
- COLL 1.86
- Revenue
- NBXG N/A
- COLL $631,449,000.00
- Revenue This Year
- NBXG N/A
- COLL $20.00
- Revenue Next Year
- NBXG N/A
- COLL $3.93
- P/E Ratio
- NBXG N/A
- COLL $16.00
- Revenue Growth
- NBXG N/A
- COLL 11.41
- 52 Week Low
- NBXG $9.31
- COLL $27.28
- 52 Week High
- NBXG $12.23
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- NBXG 38.88
- COLL 50.32
- Support Level
- NBXG $12.17
- COLL $29.33
- Resistance Level
- NBXG $12.60
- COLL $30.84
- Average True Range (ATR)
- NBXG 0.25
- COLL 0.84
- MACD
- NBXG 0.02
- COLL 0.07
- Stochastic Oscillator
- NBXG 29.21
- COLL 56.29
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.